CalciMedica (CALC)
NASDAQ:CALC
Want to see CALC full AI Analyst Report?
CALC Stock Chart & Stats
$0.62
<$0.01(0.05%)
At close: 4:00 PM EST
$0.62
<$0.01(0.05%)
Day’s Range― - ―
52-Week Range$0.46 - $7.20
Previous CloseN/A
Volume2.29K
Average Volume (3M)71.94K
Market Cap
$9.85M
Enterprise Value$7.96M
Total Cash (Recent Filing)$13.02M
Total Debt (Recent Filing)$9.70M
Price to Earnings (P/E)―
Beta0.07
Next Earnings
May 18, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.68
Shares Outstanding15,743,916
10 Day Avg. Volume167,963
30 Day Avg. Volume71,939
Financial Highlights & Ratios
PEG Ratio-54.43
Price to Book (P/B)-14.90K
Price to Sales (P/S)0.00
P/FCF Ratio-4.66K
Enterprise Value/Market Cap0.81
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.59K
Enterprise Value/Ebitda-0.36
Forecast
1Y Price Target
$10.00Price Target Upside1512.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.37
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Safety ProfileAuxora's prior testing in hundreds of patients without notable safety signals and the assessment that the observed mortality imbalance likely reflects baseline severity help de‑risk the program's clinical safety profile.
Lead Program FocusStrategic refocus on the acute pancreatitis program positions the therapy as the company's primary value driver and concentrates development resources on the most promising asset.
Regulatory StrategySecuring regulatory agreement on a pivotal acute pancreatitis trial design could establish a first‑mover advantage in an area with no approved treatments, improving commercial potential.
Bears Say
Analyst SentimentAnalyst downgrade to neutral following the trial halt signals reduced investor confidence and may pressure the stock as questions remain about the program's outlook.
Clinical Trial HaltIndependent safety committee recommendation to stop the KOURAGE trial for a safety concern removes a key anticipated catalyst and raises program uncertainty.
Pipeline Contagion RiskUnclear impact of the kidney injury safety issue on the design or prospects of the acute pancreatitis and pediatric programs introduces a risk of broader pipeline disruption.
CalciMedica News
CALC FAQ
What was CalciMedica’s price range in the past 12 months?
CalciMedica lowest stock price was $0.46 and its highest was $7.20 in the past 12 months.
What is CalciMedica’s market cap?
CalciMedica’s market cap is $9.85M.
When is CalciMedica’s upcoming earnings report date?
CalciMedica’s upcoming earnings report date is May 18, 2026 which is in 32 days.
How were CalciMedica’s earnings last quarter?
CalciMedica released its earnings results on Mar 03, 2026. The company reported -$0.68 earnings per share for the quarter, missing the consensus estimate of -$0.412 by -$0.268.
Is CalciMedica overvalued?
According to Wall Street analysts CalciMedica’s price is currently Undervalued.
Does CalciMedica pay dividends?
CalciMedica does not currently pay dividends.
What is CalciMedica’s EPS estimate?
CalciMedica’s EPS estimate is -0.28.
How many shares outstanding does CalciMedica have?
CalciMedica has 15,743,916 shares outstanding.
What happened to CalciMedica’s price movement after its last earnings report?
CalciMedica reported an EPS of -$0.68 in its last earnings report, missing expectations of -$0.412. Following the earnings report the stock price went up 14.398%.
Which hedge fund is a major shareholder of CalciMedica?
Currently, no hedge funds are holding shares in CALC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CalciMedica
CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.
CALC Stock 12 Month Forecast
Average Price Target
$10.00
▲(1512.90% Upside)
Technical Analysis
Ownership Overview
31.96% Insiders
2.78% Mutual Funds
17.79% Other Institutional Investors
45.21% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---